Survival of bronchiectatic patients with respiratory failure in ICU

被引:28
作者
Alzeer A.H. [1 ]
Masood M. [1 ]
Basha S.J. [1 ]
Shaik S.A. [2 ]
机构
[1] Division of Pulmonology, Department of Medicine, King Khalid University Hospital, Riyadh
[2] Department of Family and Community Medicine, King Khalid University Hospital, Riyadh
关键词
Intensive Care Unit; Chronic Obstructive Pulmonary Disease; Intensive Care Unit Admission; Intensive Care Unit Stay; Bronchiectasis;
D O I
10.1186/1471-2466-7-17
中图分类号
学科分类号
摘要
Background: The outcome of patients with bronchiectasis during and after their stay in the intensive care unit (ICU) has seldom been reported in the literature. Managing these patients in the ICU can be challenging because of the complex nature of their disease. This study aims to identify the in-hospital and long-term outcome of patients with bronchiectasis and respiratory failure (RF) in ICU. Methods: A retrospective study was carried out by studying all bronchiectatic patients admitted to the medical ICU for RF over a 10-year period (1995-2004). Results: The mean (± standard deviation) age of 35 patients was 63.5 ± 11.7 years and APACHE score was 22.3 ± 7.3. The 4-year mortality was 60%. Among the variables observed, age > 65 years (hazard ratio (HR): 4.15; 95% confidence interval (CI): 3.2-5.1), APACHE II score > 24 (2.6, 95% CI 1.7-3.5), intubation (2.81, 95 %CI 1.9-3.7), inotropic support (2.9, 95% CI 2.0-3.7), Home-O2 (4.0, 95% CI 2.7-5.2) and activity index (4.0, 95% CI 2.8-5.3) were associated with diminished survival in univariate analysis by Cox regression. By long rank test, survival probabilities were significantly low at these strata. Multivariate analysis of Cox proportional hazard model showed that age > 65 years (HR: 5.4, 95% CI 1.9-15.7); activity index (HR: 4.8, 95% CI 1.4-16.6); and inotropic support (HR: 3.8, 95% CI 1.5-10.1) were independently associated with reduced survival. Conclusion: The decreased survival of ICU patients was associated with age > 65 years, activity index (bedridden or wheelchair-bound) and use of inotropic support. © 2007 Alzeer et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
[1]  
Barker A.F., Bronchiectasis, N Engl J Med, 346, pp. 1383-1393, (2002)
[2]  
Annest L.S., Kratz J.M., Crawford Jr. F.A., Current results of treatment of bronchiectasis, J Thorac Cardiovasc Surg, 83, pp. 546-550, (1982)
[3]  
Sanderson J.M., Kennedy M.C., Johnson M.F., Manley D.C., Bronchiectasis: Result of surgical and conservative management: A review 393 cases, Thorax, 29, pp. 407-416, (1974)
[4]  
Ashour M., Al-Kattan K., Rafay M.A., Saja K.F., Hajjar W., Al-Fraye A.R., Current surgical therapy for bronchiectasis, World J Surg, 23, pp. 1096-1104, (1999)
[5]  
Stockley R.A., Hill S.L., Morrison H.M., Starkie C.M., Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis, Thorax, 39, pp. 408-413, (1984)
[6]  
Murphy M.B., Reen D.J., Fitzgerald M.X., Atopy, immunological changes, and respiratory function in bronchiectasis, Thorax, 39, 3, pp. 179-184, (1984)
[7]  
Naidich D.P., McCauley D.I., Khouri N.F., Stitik F.P., Siegelman S.S., Computed tomography of bronchiectasis, J Comput Assist Tomogr, 6, pp. 437-444, (1982)
[8]  
Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C., Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society, Eur Respir J Suppl, 16, pp. 5-40, (1993)
[9]  
Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E., A severity of disease classification system, Crit Care Med, 13, pp. 818-829, (1985)
[10]  
Ferris B.G., Epidemiology Standardization Project, Am Rev Respir Dis, 118, pp. 1-120, (1978)